Trending News Today: Hepatitis B Vaccine Meets Primary Goal in Trial
Top news of the day from across the health care landscape.
A late-stage study that compared VBI Vaccine’s hepatitis B virus (HBV) vaccine with GlaxoSmithKline’s Engerix-B met its primary goals, Reuters reported. According to the article, VBI’s Sci-B-Vac was administered at a 10 microgram dose versus a 20 microgram dose of Engerix-B. Overall, the seroprotection rate in all patients aged 18 and older who received Sci-B-Vac was 91.4% compared with 76.5% for those who received Engerix-B, the article reported.
A new study indicated that the annual financial impact of Parkinson disease (PD) in the United States is $52 billion, more than double previous estimates, The American Journal of Managed Care reported. According to the article, the study provided a comprehensive assessment of the total costs incurred by patients, care partners, payers, employers, health care systems, and government programs. The researchers also examined how the disease affects the personal finances of patients. The study found that the federal government spent approximately $25 billion per year providing care for individuals with PD, the article reported.
A recent analysis showed that cardiovascular risk factors (CVRFs) are prevalent in approximately half of all patients with type 1 diabetes, MD Magazine reported. According to the article, the study included 12,687 adults and compared economic outcomes between patients with type 1 diabetes with and without cardiovascular disease or CVRFs. The researchers concluded that 23% of patients had the prevalence of cardiovascular disease and 42% had CVRFs, the article reported.